Holen Sie sich die Stockscreener-App
0.4498
1.40%
-0.0064
Handel nachbörslich:
.44
-0.0098
-2.18%
Schlusskurs vom Vortag:
$0.4562
Offen:
$0.45
24-Stunden-Volumen:
116.16K
Relative Volume:
0.58
Marktkapitalisierung:
$7.69M
Einnahmen:
$4.03M
Nettoeinkommen (Verlust:
$24.32M
KGV:
-0.1046
EPS:
-4.3008
Netto-Cashflow:
$-45.76M
1W Leistung:
-1.55%
1M Leistung:
-21.50%
6M Leistung:
-43.06%
1J Leistung:
-35.83%
1-Tages-Spanne:
$0.43
$0.4699
1-Wochen-Bereich:
$0.43
$0.48
52-Wochen-Spanne:
$0.304
$1.90
Pavmed Inc Stock (PAVM) Company Profile
Firmenname
Pavmed Inc
Sektor
Branche
Telefon
(212) 949-4319
Adresse
360 MADISON AVENUE, NEW YORK, NY
Vergleichen Sie PAVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.4498 | 7.89M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Eingeleitet | Maxim Group | Buy |
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
PAVmed Q2 Earnings Miss Expectations; Market Reaction Remains Cautious - AInvest
Is PAVmed Inc. the Top Chart Pick This WeekWeekly Stock Report & AI Forecasted Entry and Exit Points - metal.it
PAVmed Reports Q2 2025 Financial Results and Developments - MSN
PAVmed reports Q2 non-GAAP EPS (5c) vs. (84c) last year - MSN
PAVmed Reports Q2 2025 Financial Results: $13.3M Net Loss, $1.2M in Lucid Diagnostics Revenue - AInvest
PAVmed Q2 2025 slides reveal dramatic cost reduction amid Lucid Diagnostics growth By Investing.com - Investing.com South Africa
PAVmed Inc (PAVM) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
PAVmed 2025 Q2 Earnings Net Loss Narrows by 17.4% - AInvest
Lucid Diagnostics Advances Towards Medicare Coverage - MSN
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
PAVmed Revenue Jumps 513% in Q2 - sharewise.com
PAVmed's EsoGuard Cancer Test Hits 2,756 Q2 Tests as Medicare Coverage Decision Nears - Stock Titan
PAVmed Inc. SEC 10-Q Report - TradingView
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results - BioSpace
Lucid Diagnostics Reports Q2 2025 Financial Results - TipRanks
PAVmed's Q2 2025 Earnings Call: Unraveling Contradictions in Medicare Strategy, FDA Timelines, and Biopharma Expansion - AInvest
Transcript : PAVmed Inc., Lucid Diagnostics Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Earnings call transcript: Lucid Diagnostics highlights Q2 2025 growth and Medicare focus - Investing.com India
Lucid Diagnostics Inc: Navigating Earnings Challenges and Strategic Growth in a Competitive Diagnostics Landscape - AInvest
What makes PAVmed Inc. stock price move sharplyShort-Term Explosive Growth - thegnnews.com
PAVmed's Q2 2025 Earnings: A Strategic Inflection Point in Healthcare Innovation and Financial Turnaround - AInvest
PAVmed PAVM 2025Q2 Earnings Preview Upside Potential Driven by Strategic Innovations - AInvest
Investors Hope for Bounce in PAVmed Inc. After SelloffCapital Preservation Forecast Insight Signal - beatles.ru
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Eastern Progress
Published on: 2025-08-05 15:46:56 - metal.it
Lucid Diagnostics to Participate in Upcoming Investor Conferences – Company Announcement - Financial Times
Cancer Prevention Leader Lucid Diagnostics Headlines Two Major Healthcare Investment Conferences This Month - Stock Titan
Trendline Breach Raises Concern for PAVmed Inc. InvestorsTriple Return Setup With Risk Control Explained - metal.it
PAVmed Inc. Forms Bullish Flag — Upside AheadEntry Plan for Oversold Reversal Stocks Released - metal.it
PAVmed Inc. Crosses 200 Day MA — Signal or NoiseReal-Time Analysis With Entry Targets In Progress - metal.it
Is PAVmed Inc. a growth stock or a value stockHigh-velocity gains - Jammu Links News
What are analysts’ price targets for PAVmed Inc. in the next 12 monthsUnlock exclusive stock analysis for investors - Jammu Links News
What analysts say about PAVmed Inc. stockUnlock powerful trading alerts for success - Jammu Links News
What are the latest earnings results for PAVmed Inc.Free Stock Selection - Jammu Links News
Does PAVmed Inc. stock perform well during market downturnsTrack high-yield stocks before they peak - Jammu Links News
When is PAVmed Inc. stock expected to show significant growthTremendous portfolio expansion - Jammu Links News
How strong is PAVmed Inc. company’s balance sheetCapitalize on emerging market sectors - Jammu Links News
What markets is BHST expanding into Is PAVmed Inc. stock a good long term investment option - Jammu Links News
PAVmed to Host Business Update Conference Call on August 14, 2025 - AInvest
Nasdaq Grants PAVmed 180-Day Extension to Meet Minimum Bid Price Rule - AInvest
Pavmed Inc. shares fall 1.22% after-hours following announcement of a business update conference call. - AInvest
PAVmed gets 180-day extension to regain Nasdaq listing compliance - MSN
PAVmed to Host Business Update Conference Call on August 14, 2025. - AInvest
PAVmed CEO and CFO to Present Q2 2025 Results and Growth Strategy Update on August 14 - Stock Titan
Pattern recognition hints at PAVmed Inc. upsideCommunity Shared Smart Money Signals Show Movement - metal.it
Should I hold or sell PAVmed Inc. stock in 2025Advanced Screener Ideas For Fast Growth - Jammu Links News
Finanzdaten der Pavmed Inc-Aktie (PAVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.74%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):